CODA completes funding for the development of chemical gene therapy for neurological diseases
Last Update: 2021-03-02
Search more information of high quality chemicals, good prices and reliable suppliers, visit
, biopharmaceutical company CODA Biotherapeutics (CODA) announced the completion of a $15 million round of financing for A-plus. The round of financing is led by Versant Ventures, MPM Capital and Astellas Venture Management.
CODA intends to use this round of financing funds to further develop the company's platform and help it consolidate its leadership position in the core therapeutic areas. In addition, the company plans to bring its chemical gene therapy platform to clinical practice to treat chronic neuropathic pain and resusctic epilepsy.
Since its establishment, CODA has completed two financings and completed a $19 million round of A financing in September 2018. The financing will bring CODA's round A financing to $34 million.
Founded in 2014 and headquartered in South San Francisco, California, CODA is a preclinical biopharmaceutical company. The company is committed to developing innovative gene therapy platforms and using revolutionary technologies in chemical genetics to regulate pathological cell activity and provide new treatments for patients with neurological disorders.
At present, CODA is genetically engineering neurotransmitter subjects and developing oral bio-use drugs for such subjects to treat neurological diseases such as chronic neuropathic pain and reseed epilepsy. CODA drugs can be delivered through viral vectors and directly used on dysfunctional neurons to activate modified subjects and regulate neuron activity. (Arterial mesh)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to firstname.lastname@example.org
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.